The article provides information on the alliance between the organization Multiple Myeloma Research Foundation (MMRF) and US Oncology Research, research network to participate in the CoMMpass study sponsored by the MMRF. The CoMMpass study will follow 1,000 newly diagnosed multiple myeloma patients ...
Facing mortality can be a paralyzing experience for some people, but for others, it may ignite a passion to accelerate life. One such person is Kathy Giusti, cofounder of the Multiple Myeloma Research Foundation (MMRF), where she served as Chief Executive Officer and President for nearly 20 ...
Multiple myeloma (MM) is an incurable disease, whose clinical heterogeneity makes its management challenging, highlighting the need for biological features to guide improved therapies. Deregulation of specific long non-coding RNAs (lncRNAs) has been shown in MM, nevertheless, the complete lncRNA transc...
noted that certain patient advocacy groups, such as the Multiple Myeloma Research Foundation, have actively enabled direct access to EAPs through partnerships with drug manufacturers. Hence, patients suffering from these cancer types may be less likely to pursue online campaigns given their ability to ...
Supported by Consiglio Nazionale delle Ricerche Ministero dell' Istruzione, dell' Università e della Ricerca (CNR-MIUR) (Rome, Italy), 2002 funds; the Leukaemia Research Fund (LRF) (United Kingdom); the Multiple Myeloma Research Foundation (New Canaan, CT); and the Hairy Cell Leukemia Research...
Human myeloma cell line IL8: Interleukin-8 mAb: Monoclonal antibody MM: Multiple myeloma MMP9: Matrix metallopeptidase 9 MSCs: Mesenchymal stromal cells OB: Osteoblast OC: Osteoclast OPG: Osteoprotegerin PBMC: Peripheral mononuclear cell PC: Plasma cell RANKL: Nuclear factor kappa-Β...
This case series assesses whether environmental exposures from the World Trade Center disaster site are associated with multiple myeloma and its precursor
Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic bone microenvironmental mechanisms cause relapse is challenging with current biological approaches. Here, we report ...
Chairman, International Myeloma Foundation, North Hollywood, CA When patients respond well to treatment for multiple myeloma, doctors can’t tell them whether they’ve been cured. That news comes 10 years later, after the patients have been monitored carefully for recurrence. “During that time,...
Multiple myeloma (MM) remains an incurable hematological malignancy disease characterized by the progressive dysfunction of the patient’s immune system. In this context, immunotherapy for MM has emerged as a prominent area of research in recent years. V